GERN (1.71) insider buying details -
tipranks -
New insider activity at Geron ( GERN -2.84%) has taken place on March 3, 2025.
In a series of significant transactions, key executives at Geron have made substantial purchases of the company’s stock. Samuels Scott Alan, EVP and CLO, acquired 15,000 shares valued at $24,150. John Scarlett, the COB, President, and CEO, purchased 12,500 shares for $22,000. Meanwhile, James Ziegler, EVP and Chief Commercial Officer, made the largest investment by buying 100,000 shares worth $160,000. These transactions highlight a strong vote of confidence in the company’s future from its top leadership.
Recent Updates on GERN stock
In the last 24 hours, Geron Corporation has experienced significant developments affecting its stock. Analysts from Scotiabank and Barclays have lowered their price targets for Geron, citing concerns over the slowdown in the launch of RYTELO, a telomerase inhibitor for lower-risk myelodysplastic syndromes. Despite Geron’s strong cash position and the FDA approval of RYTELO, the company’s revenue trends have plateaued, prompting strategic adjustments and leadership changes. The recent earnings call highlighted mixed sentiments, with achievements such as a robust cash position and FDA approval, but also challenges like flat revenue trends and increased operating expenses. Analysts remain cautious due to the slower-than-expected uptake of RYTELO, affecting their price target adjustments.
AI
